Key takeaways
- U.S. News & World Report awarded telehealth provider Found a 4.6 out of 5 rating.
- Found was named 'Best for Clinical Support' due to its insurance prior authorization assistance and compound microdosing.
- The platform offers compounded semaglutide starting at $169/month, alongside brand-name GLP-1 insurance coordination.
What happened
U.S. News & World Report has awarded telehealth platform Found a score of 4.6 out of 5 stars in its 2026-2027 evaluations, naming it the "Best for Clinical Support" among virtual weight-loss clinics. In its detailed review, the publication highlighted Found's specialized features, including customized microdosing options for compounded medications and robust administrative assistance for insurance prior authorizations and appeals.
Why it matters
Selecting an online GLP-1 clinic can be overwhelming for US buyers navigating high costs and complex insurance rules. This major national rating signals that value in the telehealth space is shifting beyond basic medication access. By spotlighting administrative support and dosing flexibility, the rating helps consumers identify platforms that help lower out-of-pocket costs through insurance navigation or offer tailored clinical protocols like microdosing to manage side effects.
What the data says
The U.S. News evaluation gave Found an overall score of 4.6, driven by a 4.9 rating for "Clinical Support." The review broke down Found's multi-tiered pricing model, which charges a monthly membership fee alongside medication costs:
- Membership Fees: $49 per month if utilizing insurance, or $99 per month for self-pay patients seeking brand-name GLP-1s.
- Compounded Medications: Compounded semaglutide starts at $169 per month under a 12-month commitment. Compounded tirzepatide is listed starting at $2,939 per month for a 12-month plan.
- Brand-Name Cash Prices: Wegovy pens range from $349 to $399 per month depending on strength, while Wegovy pills range from $149 to $299 per month. Zepbound cash prices range from $299 to $449 per month depending on dosage. Foundayo is priced between $149 and $299 per month.
On the clinical side, U.S. News highlighted that Found provides compounded options with specific microdosing protocols, alongside one-on-one access to certified health coaches, dosing adjustments, and active support for managing glp-1-side-effects.
How it compares
Compared to other options in the telehealth market, Found’s model blends brand-name insurance navigation with compounded alternatives. While some platforms only offer flat-rate compounded drugs, Found's clinical team actively manages prior authorizations and appeals for brand-name medications like Ozempic, Wegovy, Mounjaro, and Zepbound.
At a starting price of $169 per month for compounded semaglutide (on a annual plan), Found sits on the highly competitive end of the market when compared to other services listed on our compare tool. However, the $2,939 per month starting price for compounded tirzepatide on a 12-month plan is exceptionally high compared to market averages, where compounded tirzepatide is typically found for under $400 per month. Prospective buyers should explore the cheapest-telehealth-glp-1 directory to compare overall monthly commitments.
Additionally, Found’s support for "microdosing"—or starting at ultra-low, highly customized doses to mitigate nausea and other gastrointestinal issues—is a distinct clinical feature that is not universally advertised by standard, pre-filled pen providers.
How this fits the bigger picture
The positive rating for Found comes amidst a broader push by mainstream publications to evaluate the rapidly growing virtual obesity care market. We previously covered this trend when U.S. News Unveils First GLP-1 Telehealth Platform Ratings, establishing a new benchmark for how these services are vetted.
As consumers look for ways to bypass high out-of-pocket costs, telehealth platforms are increasingly forced to act as administrative allies. Navigating insurance is notoriously difficult for obesity medications. When coverage is denied, patients frequently turn to compounded alternatives. This shift highlights why having access to a platform that can seamlessly transition a patient between brand-name insurance appeals and compounded-vs-brand-name-semaglutide is becoming a major selling point.
Furthermore, as the FDA closely monitors the compounding space, telehealth companies that offer robust clinical oversight, structured coaching, and legitimate pharmacy partnerships are earning higher trust scores than "prescription-only" mills.
What happens next
The telehealth landscape is expected to grow even more competitive as platforms adapt to changing drug availability and regulatory updates. Consumers should watch for how platforms like Found adjust their compound pricing—especially for tirzepatide—to remain competitive with flat-rate digital clinics.
Additionally, as insurance coverage rules for weight-loss medications continue to evolve, the success rate of virtual clinics handling prior authorizations will likely dictate consumer retention. Patients considering signing up for a GLP-1 program can research current options, pricing structures, and clinical offerings on our providers page.
Disclaimer: CompareRx does not provide medical advice. Consult with a qualified healthcare provider before starting any medication or weight-loss program.